Arrowhead Pharmaceuticals Inc. – Plans of Reorganization, Merger, Acquisition or Similar

EX-2.1

from 10-Q 55 pages “The Use of the Following Notation in This Exhibit Indicates That a Confidential Portion Has Been Omitted Pursuant to a Request for Confidential Treatment and the Omitted Material Has Been Filed Separately With the Commission: [***]” Asset Purchase and Exclusive License Agreement by and Between Arrowhead Research Corporation, a Delaware Corporation and Novartis Institutes for Biomedical Research, Inc., a Delaware Corporation March 3, 2015

12/34/56

EX-2.1

from 10-K 81 pages Certain Confidential Portions of This Exhibit Were Omitted and Replaced With “[**]”. a Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934. Stock and Asset Purchase Agreement Dated as of October 21, 2011 Among Arrowhead Research Corporation, Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd

12/34/56

EX-2.1

from 8-K 88 pages Agreement and Plan of Merger by and Among Unidym, Inc., Unidym Acquisition, LLC, Carbon Nanotechnologies, Inc. and the Stockholder Representative Dated as of March 21, 2007

12/34/56

EX-2.1

from 10KSB ~20 pages Plan of reorganization, merger, acquisition or similar

12/34/56

Arrowhead Pharmaceuticals Inc. – Plans of Reorganization, Merger, Acquisition or Similar

Search in Documents

Key Exhibits

External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

Arrowhead Pharmaceuticals Inc. – Plans of Reorganization, Merger, Acquisition or Similar Watch

Search in Documents

Key Exhibits

External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

Arrowhead Pharmaceuticals Inc. – Plans of Reorganization, Merger, Acquisition or Similar